MHC-I genotype and tumor mutational burden predict response to immunotherapy
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
MHC-I genotype and tumor mutational burden predict response to immunotherapy
Authors
Keywords
-
Journal
Genome Medicine
Volume 12, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-05-19
DOI
10.1186/s13073-020-00743-4
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Tumor mutational load predicts survival after immunotherapy across multiple cancer types
- (2019) Robert M. Samstein et al. NATURE GENETICS
- First-Line Nivolumab Plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers
- (2019) Neal Ready et al. JOURNAL OF CLINICAL ONCOLOGY
- Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non–Small-Cell Lung Cancer: Results From the CA209-003 Study
- (2018) Scott Gettinger et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial
- (2018) Philippe Armand et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
- (2018) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma
- (2018) Diana Miao et al. SCIENCE
- Microsatellite instability status determined by next-generation sequencing and compared with PD-L1 and tumor mutational burden in 11,348 patients
- (2018) Ari Vanderwalde et al. Cancer Medicine
- Prevalence of PDL1 Amplification and Preliminary Response to Immune Checkpoint Blockade in Solid Tumors
- (2018) Aaron M. Goodman et al. JAMA Oncology
- Evolutionary Pressure against MHC Class II Binding Cancer Mutations
- (2018) Rachel Marty et al. CELL
- Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response
- (2018) Peng Jiang et al. NATURE MEDICINE
- Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma
- (2018) Noam Auslander et al. NATURE MEDICINE
- Fundamental Mechanisms of Immune Checkpoint Blockade Therapy
- (2018) Spencer C. Wei et al. Cancer Discovery
- Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic
- (2018) T A Chan et al. ANNALS OF ONCOLOGY
- Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial
- (2018) Frank Stephen Hodi et al. LANCET ONCOLOGY
- The Marriage Between Genomics and Immunotherapy: Mismatch Meets Its Match
- (2018) Vivek Subbiah et al. ONCOLOGIST
- NetMHCpan-4.0: Improved Peptide–MHC Class I Interaction Predictions Integrating Eluted Ligand and Peptide Binding Affinity Data
- (2017) Vanessa Jurtz et al. JOURNAL OF IMMUNOLOGY
- Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers
- (2017) Aaron M. Goodman et al. MOLECULAR CANCER THERAPEUTICS
- Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
- (2017) Dung T. Le et al. SCIENCE
- Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy
- (2017) Diego Chowell et al. SCIENCE
- Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden
- (2017) Zachary R. Chalmers et al. Genome Medicine
- Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
- (2016) Willy Hugo et al. CELL
- Landscape of tumor-infiltrating T cell repertoire of human cancers
- (2016) Bo Li et al. NATURE GENETICS
- PD-1–PD-L1 immune-checkpoint blockade in B-cell lymphomas
- (2016) Aaron Goodman et al. Nature Reviews Clinical Oncology
- Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
- (2016) Jesse M. Zaretsky et al. NEW ENGLAND JOURNAL OF MEDICINE
- NetMHCpan-3.0; improved prediction of binding to MHC class I molecules integrating information from multiple receptor and peptide length datasets
- (2016) Morten Nielsen et al. Genome Medicine
- Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity
- (2015) Michael S. Rooney et al. CELL
- PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy
- (2015) S. P. Patel et al. MOLECULAR CANCER THERAPEUTICS
- Comprehensive analysis of cancer-associated somatic mutations in class I HLA genes
- (2015) Sachet A Shukla et al. NATURE BIOTECHNOLOGY
- PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
- (2015) Dung T. Le et al. NEW ENGLAND JOURNAL OF MEDICINE
- TCR contact residue hydrophobicity is a hallmark of immunogenic CD8+T cell epitopes
- (2015) Diego Chowell et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Genomic correlates of response to CTLA-4 blockade in metastatic melanoma
- (2015) E. M. Van Allen et al. SCIENCE
- Immunogenicity of somatic mutations in human gastrointestinal cancers
- (2015) E. Tran et al. SCIENCE
- Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
- (2015) N. A. Rizvi et al. SCIENCE
- OptiType: precision HLA typing from next-generation sequencing data
- (2014) András Szolek et al. BIOINFORMATICS
- Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens
- (2014) Matthew M. Gubin et al. NATURE
- Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
- (2014) Alexandra Snyder et al. NEW ENGLAND JOURNAL OF MEDICINE
- Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing
- (2013) Garrett M Frampton et al. NATURE BIOTECHNOLOGY
- Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting
- (2012) Hirokazu Matsushita et al. NATURE
- Expression of tumour-specific antigens underlies cancer immunoediting
- (2012) Michel DuPage et al. NATURE
- The Major Genetic Determinants of HIV-1 Control Affect HLA Class I Peptide Presentation
- (2010) SCIENCE
- Biopython: freely available Python tools for computational molecular biology and bioinformatics
- (2009) P. J. A. Cock et al. BIOINFORMATICS
- Graft-versus-leukemia effects of transplantation and donor lymphocytes
- (2008) H.-J. Kolb BLOOD
- Epitope Landscape in Breast and Colorectal Cancer
- (2008) N. H. Segal et al. CANCER RESEARCH
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now